FDA to Accelerate the Approval of Lurbinectedin in Small Cell Lung Cancer - Targeted Oncology

  1. FDA to Accelerate the Approval of Lurbinectedin in Small Cell Lung Cancer  Targeted Oncology
  2. FDA grants priority review to lurbinectedin for relapsed small cell lung cancer  Healio
  3. PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug  European Biotechnology
  4. PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer  BioSpace
  5. View Full Coverage on Google News


Comments

Popular posts from this blog